Multiple Sclerosis, Relapsing-Remitting — Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
Citation(s)
A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta 1a (Rebif®) in Patients With Relapsing Remitting Multiple Sclerosis Who Have Relapsed On Therapy